Skip to main content
SpringerLink
Log in

Circulating tumour DNA-guided adjuvant chemotherapy in colorectal carcinoma

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Approximately 20% of locoregional colorectal carcinoma (CRC) relapse after standard of care treatment. Therefore, it is necessary to personalize our adjuvant strategies and define this subgroup, which remains at high risk after treatment. Circulating tumour DNA (ctDNA) is cell-free DNA from apoptotic cancer cells, which carries the whole genome information of the primary tumour and has emerged as good candidate to guide our therapy decisions in the future. It was shown that high levels of ctDNA after adjuvant chemotherapy is a poor prognostic factor. Moreover, it was presented at ESMO 2019 in Barcelona that patients with advanced colorectal carcinomas and ctDNA-positive samples after surgery had a significantly decreased 2‑year disease-free survival in comparison to ctDNA-negative patients. That means, ctDNA could be a tool to select this high-risk subgroup in advanced CRC in order to prolong or intensify adjuvant chemotherapy and to avoid insufficient treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9.

    Article  Google Scholar 

  3. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.

    Article  CAS  Google Scholar 

  4. Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016;7:48832–41.

    Article  Google Scholar 

  5. Murtaza M, Dawson SJ, Pogrebniak K, et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun. 2015;6:8760.

    Article  Google Scholar 

  6. Wong SQ, Raleigh JM, Callahanet J, et al. Circulating tumor DNA analysis and functional imaging provide complementary approaches for comprehensive disease monitoring in metastatic melanoma. JCO Precis Oncol. 2017;1:1–14.

    CAS  Google Scholar 

  7. Yao J, Zang W, Ge Y, et al. RAS/BRAF circulating tumor DNA mutations as a predictor of response to first-line chemotherapy in metastatic colorectal cancer patients. Can J Gastroenterol Hepatol. 2018; https://doi.org/10.1155/2018/4248971.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Bachet JB, Bouché O, Taieb J, et al. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol. 2018;29(5):1211–9.

    Article  CAS  Google Scholar 

  9. Tsao SC, Weiss J, Hudson C, et al. Monitoring response to therapy in melanoma by quantifying circulating tumourDNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep. 2015;5:11198.

    Article  Google Scholar 

  10. Li M, Chen WD, Papadopoulos N, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol. 2009;27:858–63.

    Article  Google Scholar 

  11. Garrigou S, Perkins G, Garlan F, et al. A study of Hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker. Clin Chem. 2016;62:1129–39.

    Article  CAS  Google Scholar 

  12. Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 2019; https://doi.org/10.1001/jamaoncol.2019.3616.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Taieb J, Taly V, Vernerey D, et al. Analysis of circulating tumor DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: prognostic and predictive value for adjuvant treatment duration. Annals of Oncology. 2019;30(5):v867.

Download references

Author information

Authors and Affiliations

  1. Department of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Barmherzige Schwestern, Seilerstaette 4, 4010, Linz, Austria

    Andreas Reichinger MD

  2. Gastrointestinal Cancer Center, Ordensklinikum Linz, Linz, Austria

    Holger Rumpold

Authors
  1. Andreas Reichinger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Holger Rumpold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Reichinger MD.

Ethics declarations

Conflict of interest

A. Reichinger and H. Rumpold declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reichinger, A., Rumpold, H. Circulating tumour DNA-guided adjuvant chemotherapy in colorectal carcinoma. memo 13, 334–336 (2020). https://doi.org/10.1007/s12254-020-00607-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-020-00607-y

Keywords

Search

Navigation